STOCK TITAN
  1. Home
  2. News
  3. TRVN

Trevena Inc - TRVN STOCK NEWS

Welcome to our dedicated news page for Trevena (Ticker: TRVN), a resource for investors and traders seeking the latest updates and insights on Trevena.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Trevena's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Trevena's position in the market.

News
Trevena Reports Fourth Quarter 2023 Results and Provides Corporate Update
Rhea-AI Summary
Trevena, Inc. (TRVN) focuses on developing TRV045, a novel S1P receptor modulator for chronic pain and epilepsy. The company reduces OLINVYK commercial support due to challenging hospital environment, evaluating strategic alternatives for OLINVYK. TRV045 shows positive proof-of-concept studies in neuropathic pain and epilepsy, progresses towards Phase 2 readiness. Financially, the company reports a net loss in the fourth quarter of 2023, with cash and cash equivalents at $33.0 million as of December 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.04%
Tags
earnings
-
News
Trevena Announces the Closing of $4 Million Concurrent Private Placement and Warrant Exercise
Rhea-AI Summary
Trevena, Inc. (TRVN) closes private placement offering, raising approximately $4 million in gross proceeds for general corporate and working capital purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.43%
Tags
none
-
News
Trevena Inc. Announces $4 Million Concurrent Private Placement and Warrant Exercise
Rhea-AI Summary
Trevena Inc. (TRVN) announced a private placement and induced warrant exercise, expecting to raise approximately $4 million in gross proceeds. H.C. Wainwright & Co. is the exclusive placement agent for the offerings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.85%
Tags
none
News
Trevena Announces TRV045 Presentation at the American College of Neuropsychopharmacology 62nd Annual Meeting
Rhea-AI Summary
Trevena, Inc. (Nasdaq: TRVN) announced promising results of TRV045 in nonclinical models of neuropathic pain, targeting the S1P1 receptor without causing lymphopenia. The poster presentation at the 62nd Annual Meeting for the American College of Neuropsychopharmacology discussed the potential utility of TRV045 for the treatment of chemotherapy-induced peripheral neuropathy (CIPN) and its collaboration with the NIH to evaluate TRV045 for epilepsy and nonopioid pain treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.39%
Tags
none
-
News
Trevena Awarded OLINVYK Agreement with Premier, Inc.
Rhea-AI Summary
Trevena Inc. (Nasdaq: TRVN) has secured a national group purchasing agreement for OLINVYK with Premier, Inc., effective December 1, 2023. Premier members now have the option to benefit from special pricing and terms pre-negotiated for OLINVYK, a significant development for the company's commercialization efforts.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.39%
Tags
none
-
News
Trevena Announces Acceptance of Abstract Examining the Use of OLINVYK in Patients with Acute Burn Injuries
Rhea-AI Summary
Trevena, Inc. (Nasdaq: TRVN) announced the acceptance of the RELIEVE study abstract at the 2024 ABA Annual Meeting. The study focused on evaluating OLINVYK for patients with acute burn injuries. Results will be presented in April 2024. Dr. David Hill led the single-center trial, comparing OLINVYK with other IV opioids.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.34%
Tags
none
News
Trevena Reports Third Quarter 2023 Results and Provides Business Update
Rhea-AI Summary
Trevena, Inc. (Nasdaq: TRVN) reported promising proof-of-concept data for TRV045 studies, favorable safety and tolerability topline data, and a strengthened balance sheet with a $15 million R-Bridge tranche. TRV045 demonstrated CNS target engagement and encouraging overall results in two proof-of-concept studies. Three OLINVYK abstracts were presented at ASA. The Company received a $15 million tranche from ex-US royalty-based financing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.17%
Tags
earnings
-
News
Trevena to Release Third Quarter 2023 Financial Results on November 14, 2023
Rhea-AI Summary
Trevena, Inc. (Nasdaq: TRVN) to Release Third Quarter 2023 Financial Results and Host Conference Call & Webcast at 8:00 a.m. ET. The company will discuss financial performance and future prospects, featuring remarks by key executives and a renowned medical expert. Investors can access the webcast via the provided links.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.15%
Tags
earnings
-
News
Trevena Announces Completion of Initial Analysis of OLINVYK Continuous Respiratory Monitoring Data from VOLITION Study and Presentation at American Society of Anesthesiologists Conference
Rhea-AI Summary
Trevena, Inc. completes initial analysis of OLINVYK respiratory monitoring data from VOLITION study, to be presented at ASA meeting in October. No drug-related serious adverse events (SAEs) or deaths reported. Study shows potential positive impact on respiratory outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.16%
Tags
none
News
Trevena Announces Receipt of $15 Million Non-Dilutive Tranche and Provides General Business Update
Rhea-AI Summary
Trevena, Inc. receives $15 million tranche from ex-US royalty-based financing triggered by first commercial sale of OLINVYK in China. New respiratory data from VOLITION study expected in 3Q 2023. Three OLINVYK abstracts accepted for presentation at ASA Meeting in 4Q 2023. Company to participate in HC Wainwright conference. Conference call on September 6 to discuss TRV045 data.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.29%
Tags
none
Stock TRVN logo
Trevena Inc

Nasdaq:TRVN

TRVN Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

TRVN Stock Data

6.99M
18.10M
0.92%
7.95%
0.62%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Chesterbrook

About TRVN

trevena, inc. is a clinical stage biopharmaceutical company that discovers, develops, and intends to commercialize innovative therapies that use a novel approach to target g protein coupled receptors, or gpcrs. we are dedicated to providing value to patients and healthcare providers by improving patient outcomes and reducing healthcare costs. we have identified four biased ligand drug candidates: trv130, an fda-designated breakthrough therapy, is currently in phase 3 testing for the intravenous treatment of acute moderate to severe pain; trv027 was evaluated in a phase 2b study for the treatment of acute heart failure; trv734 has completed phase 1 testing for oral treatment of acute and chronic pain; and trv250 is in preclinical development for the treatment of migraine. in addition, trevena has an early stage portfolio of drug discovery programs currently in lead optimization.